查詢結果分析
相關文獻
- Impact of Comorbidity on Survival for Locally Advanced Head and Neck Cancer Patients Treated by Radiotherapy or Radiotherapy Plus Chemotherapy
- 輔助性中醫治療對於接受放射及化學治療之頭頸癌住院病人之效益
- 挽救性手術後再次輔助性放射治療於復發性頭頸部鱗狀上皮細胞癌患者之適用性
- 輔助性中醫治療對於接受放射及化學治療之頭頸癌住院病人之效益
- 頭頸癌病患放射治療合併頭頸部出血的處置
- Malignant Primary Extragonadal Germ Cell Tumors of Mediastinum--An Analysis of Clinical and Radiological Features in 15 Cases
- Radiation Therapy in Primary Central Nervous System Lymphoma
- Implications of a Failed Prospective Trial of Adjuvant Therapy after Radical Hysterectomy for Stage Ib-IIa Cervical Carcinoma with Pelvic Node Metastases
- Definitive Radiotherapy with Or Without Chemotherapy for Resectable Head and Neck Cancer
- 晚期鼻咽癌同步化學放射治療與單獨放射治療臨床結果之比較--隨機分組試驗初步報告
頁籤選單縮合
題名 | Impact of Comorbidity on Survival for Locally Advanced Head and Neck Cancer Patients Treated by Radiotherapy or Radiotherapy Plus Chemotherapy=共病因子對於局部晚期頭頸癌病患接受放射治療或合併化學治療後存活率之影響 |
---|---|
作者姓名(中文) | 劉建廷; 邱泰然; 黃泰霖; 簡志彥; 方富民; | 書刊名 | 長庚醫誌 |
卷期 | 33:3 2010.05-06[民99.05-06] |
頁次 | 頁283-291 |
分類號 | 416.21 |
關鍵詞 | 共病因子; Charlson共病因子指標; 頭頸癌; 放射治療; 化學治療; Comorbidity; Charlson comorbidity index; Head and neck cancer; Radiotherapy; Chemotherapy; |
語文 | 英文(English) |
中文摘要 | 2000 2003 214 Charlson 71 (33%) (13.6%) (p 0.05) 21.9% 24.4% Charlson 25.9% 26.9%.8% 28.3%.5% 7.5% Charlson |
英文摘要 | Background: The aim of this study was to investigate the impact of comorbidity on survival for patients with locally advanced head and neck squamous cell carcinoma (HNSCC). Methods: A total of 214 patients with locally advanced HNSCC, treated with radiotherapy (RT) or RT plus chemotherapy (CT) from January 2000 to December 2003, were included. Comorbidity was scored by the Charlson comorbidity index (CCI). The patient-, tumor-, and treatment-related variables were recorded and overall survival (OS) and disease specific survival (DSS) were calculated. Results: Seventy-one patients (33%) had at least one comorbid condition. The most common comorbid condition was liver disease (13.6%). Higher CCI scores were not significantly correlated with exposure to smoking, alcohol, or betel quid, but were associated with older age, fewer years of education years, and no CT (p < 0.05). The 3-year OS and DSS rates were, respectively, 21.9% and 24.4% for all patients; 25.9% and 26.9% for those with CCI scores of 0, 21.8% and 28.3% for scores of 1, and 3.5% and 7.5% for scores ≥ 2. Multivariate analysis revealed that a CCI score ≥ 2, stage IV disease, a RT dose < 70 Gy, and no CT were significant predictors of poorer OS and DSS. Conclusions: Our data reveal the significant survival impact of comorbidity on patients with locally advanced HNSCC treated by RT or RT plus CT. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。